Kymera Therapeutics’ (KYMR) Buy Rating Reaffirmed at Truist Financial

Truist Financial reaffirmed their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report published on Friday morning,Benzinga reports. They currently have a $150.00 price target on the stock, up from their prior price target of $136.00.

Several other analysts have also issued reports on KYMR. Bank of America raised their price target on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Mizuho upped their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, July 16th. Loop Capital set a $132.00 target price on shares of Kymera Therapeutics in a research note on Thursday. Guggenheim lifted their target price on Kymera Therapeutics from $135.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. Finally, Piper Sandler restated an “overweight” rating and set a $140.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $137.92.

Kymera Therapeutics Trading Up 3.3%

KYMR opened at $126.63 on Friday. The business has a 50 day moving average of $114.93 and a 200-day moving average of $96.35. The stock has a market capitalization of $10.53 billion, a price-to-earnings ratio of -34.98 and a beta of 1.98. Kymera Therapeutics has a 1-year low of $55.66 and a 1-year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.65% and a negative net margin of 285.33%. The company’s revenue was up .0% compared to the same quarter last year. During the same period last year, the firm posted ($0.94) EPS. Equities analysts predict that Kymera Therapeutics will post -3.85 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider owned 50,254 shares of the company’s stock, valued at $5,871,174.82. The trade was a 11.25% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its position in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares in the last quarter. Abel Hall LLC lifted its holdings in Kymera Therapeutics by 4.0% during the 3rd quarter. Abel Hall LLC now owns 4,870 shares of the company’s stock valued at $544,000 after purchasing an additional 189 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Kymera Therapeutics by 1.8% in the second quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company’s stock valued at $1,267,000 after buying an additional 200 shares in the last quarter. Glenmede Trust Co. NA boosted its position in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after buying an additional 235 shares in the last quarter. Finally, Cetera Investment Advisers boosted its position in Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after buying an additional 252 shares in the last quarter.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.